|
Research Overview
Dr. Broadhead’s areas of specialization include the sociology of health, deviance, drugs and society and qualitative methods. His research interests include innovative methods to combat HIV and related diseases among injection drug users and methodological approaches to accessing and studying “hidden populations.” Along with Douglas D. Heckathorn, Dr. Broadhead is credited with developing the “peer-driven intervention” (PDI) outreach model. Since 1988, he has served as the principal investigator of several multi-year HIV-prevention community demonstration projects sponsored by the National Institute on Drug Abuse, the Centers for Disease Control and Prevention, and the Open Society Institute. He is presently directing a multi-year PDI study in three different cities in Yaroslavl Oblast, Russia and has consulted on the implementation of PDIs and the training of their program staff in Thailand, Vietnam, and China. In 2004, Dr. Broadhead was the recipient of a five-year Independent Scientist Award (K02) from the NIH/National Institute on Drug Abuse.
Education
Ph.D., University of California-San Francisco, 1978 (sociology)
M.S., Portland State University, 1974 (sociology)
B.S., University of Oregon, 1969 (sociology)
Featured Publications
1999 “The impact of a needle exchange’s closure,” (with Yael van Hulst and Douglas D. Heckathorn) Public Health Reports 114 (September/October): 439-447.
1999 “HIV prevention for drug injectors in Yaroslavl, Russia: a peer-driven intervention and needle exchange,” (with Boris Sergeyev, Tatyana Oparina, Tatyana P. Rumyansteva, Valerii Voklanevskii, Douglas D. Heckathorn and Heather Madray), Journal of Drug Issues 29 (4): 777-804.
1999 “Termination of an established needle exchange: a study of claims and their impact,” (with Yael van Hulst and Douglas D. Heckathorn) Social Problems, vol. 46 (February): 48-66.
2001 "Hustlers in AIDS prevention research: ethnographers, outreach workers and injection drug users," Addiction Research and Theory 9 (6): 545-556.
2001 “A methodology for reducing subject duplication and impersonation in samples of hidden populations,” (with Douglas D. Heckathorn and Boris Sergeyev) Journal of Drug Issues 32 (2) : 543-564.
2002 “Extension of respondent driven sampling: a new approach to the study of injection drug users aged 18-215,” (with Douglas D. Heckathorn, Salaam Semann and James Hughes) AIDS and Behavior 10 (March) 5: 55-67.
2002 “Safer injection rooms in North America: their place in public policy and health initiatives,” (with Thomas Kerr, Jean-Paul C. Grund and Frederick Altice, Journal of Drug Issues, vol. 32 (Winter) # 1: 329-355.
2002 “Increasing drug users’ adherence to HIV therapeutics,” (with Douglas D. Heckathorn, Frederick Altice, Yael van Hulst, Michael Carbone, Gerald Friedland, Patrick O’Connor and Peter Selwyn), Social Science and Medicine vol. 55: 235-46.
2003 “Safer injection sites in New York City: a utilization survey of injection drug users,” (with Casey A. Borch, Yael van Hulst, Jason Farrell, Wayne J. Villemez and Frederick L. Altice), Journal of Drug Issues vol. 33 (3): 733-750.
2003 Special Editor, “Introduction: Safer injection facilities: obstacles, proposals, polices and program evaluations,” Journal of Drug Issues vol. 33 (3): 533-537.
2005 “Law enforcement influences on HIV prevention for injection drug users: evidence from a cross-border project in China and Vietnam,” (with T.L. Hammett, N.A. Bartlett, C.Yi, D. Ngu, D.D. Cuong, N. M. Phuong, N.H. Tho, L.K.Van, L.Wei, M. Donghua, X.S. Xiang, H. Chen, H.N. Quyen, R.S. Broadhead, D.C. Des Jarlais), International Journal of Drug Policy 16 (August) 235-245.
Forthcoming “Trust and other characteristics associated with health care utilization by injection drug users,” (with Stephen Ostertag and Bradley R. Wright) Journal of Drug Issues.
Forthcoming “Peer-Driven HIV interventions for drug injectors in Russia: first year impact results of a field experiment,” (with Valerii L. Volkanevsky, Tamara Rydanova, Marina Ryabkova, Casey Borch, Yael van Hulst, Andrew Fullerton, Boris Sergeyev, and Douglas D. Heckathorn) International Journal of Drug Policy.
|
